Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.44 |
| ▸ | FAAH | O00519 | 5/20 | 0.42 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269233 | 0.88 | FAAH (0.49) | DGAT1FAAHALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL3268460 | 0.86 | FAAH (0.49) | FAAHALDH1A1MAPT | |
| SCHEMBL3442740 | 0.85 | USP2 (0.52) | DGAT1FAAHUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3274874 | 0.84 | DGAT1 (0.45) | DGAT1FAAHUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3270535 | 0.81 | FAAH (0.48) | DGAT1FAAHALDH1A1MAPT | |
| SCHEMBL3268417 | 0.81 | FAAH (0.48) | DGAT1FAAHALDH1A1MAPK1MAPT | |
| SCHEMBL3442823 | 0.80 | USP2 (0.42) | FAAHUSP2ALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL3268031 | 0.79 | FAAH (0.64) | DGAT1FAAHALDH1A1CA2CA9 | |
| SCHEMBL3761160 | 0.79 | FAAH (0.66) | FAAHALDH1A1SMN1; SMN2HSD17B10HTT | |
| SCHEMBL3272241 | 0.79 | FAAH (0.48) | DGAT1FAAHUSP2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234389-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234389-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234389-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2199282-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-23 | — | — | EP | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234389-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | DGAT1 256/4885FAAH 1/4885USP2 793/4885 |
| US-20090163508-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | DGAT1 256/4885FAAH 1/4885USP2 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.